Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAPE in Early-Stage CTCL
NCT02213861Phase 2Unknown
- Sponsor
- TetraLogic Pharmaceuticals
- Start
- Nov 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of remetinostat in cutaneous T-cell lymphoma (CTCL) (3 arms), sponsored by TetraLogic Pharmaceuticals. Primary endpoint: Composite Assessment of Index Lesion Severity at 52 weeks. Status: unknown.
02
Drugs
remetinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02213861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213861.